Intravenous Alteplase for Stroke: Beyond the Guidelines and in Particular Clinical Situations
Stroke 38:2612-2618, De Keyser,J.,et al, 2007
Thrombolysis for Acute Ischemic Stroke in the Unwitnessed or Extended Therapeutic Time Window
Neurol 94:e1241-e1248, Tsivgoulis, G.,et al, 2020
Intravenous Thrombolysis in Unwitnessed Stroke Onset: MR WITNESS Trial Results
Ann Neurol 83:980-993, Schwamm, L.H.,et al, 2018
Thrombolysis of Basilar Artery Occlusion: Impact of Baseline Ischemia and Time
Ann Neurol 73:688-694, Strbian, D.,et al, 2013
Thrombolysis with Alteplase 3 to 4.5 Hours After Acute Ischemic Stroke
NEJM 359:1317-1329,1393, Hacke,W.,et al, 2008
Asymptomatic Hemorrhage After Thrombolysis May Not Be Benign: Prognosis by Hemorrhage Type in the Canadian Alteplase for Stroke Effectiveness Study Registry
Stroke 38:7579, Dzialowski,I.,et al, 2007
MRI-Based and CT-Based Thrombolytic Therapy in Acute Stroke Within and Beyond Established Time Windows
Stroke 38:2640-2645, Schellinger,P.D.,et al, 2007
Outcome and Symptomatic Bleeding Complications of Intravenous Thrombolysis Within 6 Hours in MRI-Selected Stroke Patients
Stroke 37:852-858, Thomalla,G.,et al, 2006
MRI Screening Before Standard Tissue Plasminogen Activator Therapy Is Feasible and Safe
Stroke 36:1939-1943, Kang,D.-W.,et al, 2005
The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase
Stroke 36:66-73, Hacke,W.,et al, 2005